Status: Recruiting
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line Camrelizumab and Apatinib with or without intravenous FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma (HCC).
Participants needed: 326
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Linhui PengUpdated: Dec 16, 2025Locations: 1
Eligibility criteria
Patients volunteered to participate in this study and signed informed consent; [+15]
Known cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, and fibrolamell... [+31]